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Abstract
Coincident with the opioid epidemic in the United States has been a dramatic increase in
the number of children born with neonatal abstinence syndrome (NAS), a form of withdrawal
resulting from opioid exposure during pregnancy. Many research efforts on NAS have focused
on short-term care, including acute symptom treatment and weaning of the infants off of their
drug dependency prior to authorizing their release. However, investigations into the long-term
effects of prenatal opioid exposure (POE) on brain development, from the cellular to the
behavioral level, have not been as frequent. Given the importance of the perinatal period for
human brain development, opioid-induced disturbances in the formation and function of nascent
synaptic networks and glia have the potential to impact brain connectivity and cognition long
after the drug supply is cut off shortly after birth. In this review, we will summarize the current
state of NAS research, bringing together findings from human studies and preclinical animal
models to highlight what is known about how POE can induce significant, prolonged deficits in
brain structure and function. With rates of NAS continuing to rise, particularly in regions that
already face substantial socioeconomic challenges, we speculate as to the most promising
avenues for future research to alleviate this growing multigenerational threat.

Significance Statement
There has recently been a significant rise in the number of infants born with neonatal
abstinence syndrome (NAS) after prenatal opioid exposure. Though little is known about the
long-term effects of early life opioid exposure on brain connectivity, this review attempts to
consolidate the existing literature from both preclinical models and humans. Elevated NAS
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diagnosis rates suggest that this public health crisis will only worsen with time. Therefore, there
is an immediate need to understand the impact of prenatal opioids on brain development to
predict future healthcare concerns and develop strategies to improve long-term outcomes in
children born with NAS.

Introduction
Since the 1990s, the rate of abuse of opioid drugs has risen dramatically in the United
States (Scholl, Seth, Kariisa, Wilson, & Baldwin, 2018). One of the most significant outcomes of
this opioid epidemic has been a sharp rise in the incidence of neonatal abstinence syndrome
(NAS). NAS is the clinical diagnosis used to describe the collection of signs and symptoms
commonly observed in the newborns of mothers who abused certain drugs, such as opioids,
during pregnancy (NAS specifically resulting from opioids has also been termed NOWS, for
neonatal opioid withdrawal syndrome). The fetus develops a physical dependence on these drugs
and, after being separated from the supply of drug at birth, the infant soon displays the symptoms
of withdrawal, typically within 72 hours. Signs and symptoms can include irritability, tremors,
excessive crying, poor feeding, diarrhea, and, in some of the more severe cases, seizures
(Kocherlakota, 2014). Scoring scales, such as the Finnegan Neonatal Abstinence Scoring
System, are used to numerically evaluate infants displaying signs of NAS and help determine
appropriate treatment plans (Finnegan, Connaughton, Kron, & Emich, 1975). Length of hospital
stays for affected infants average 16 days but vary depending on the severity and duration of
symptoms (Hudak & Tan, 2012). In addition, maternal drug use has also been correlated with
increased risk of sudden infant death syndrome (SIDS), with some estimates at nearly a 4-fold
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increase compared to the general population (Cohen, Morley, & Coombs, 2015; Kandall, Gaines,
Habel, Davidson, & Jessop, 1993).
Incidence of NAS in the United States has rapidly increased in recent years (S. W.
Patrick, Davis, Lehmann, & Cooper, 2015; S. W. Patrick et al., 2012). The prevalence of NAS
rose to 6.5 cases per 1,000 neonatal hospitalizations reported in 2014 compared to 1.5 per 1,000
in 1999 (Haight, Ko, Tong, Bohm, & Callaghan, 2018). In West Virginia, where access to
treatment facilities for opioid abuse is limited (Brown, Goodin, & Talbert, 2018), the rate of
NAS from October 2016 to December 2017 was 52.6 cases per 1,000 live births (Umer et al.,
2019). NAS represents a serious emotional toll for the families of these children and a significant
financial burden for healthcare providers, with approximately $462 million in NAS treatment
costs financed by Medicaid as recently as 2014 (Winkelman, Villapiano, Kozhimannil, Davis, &
Patrick, 2018), prompting considerable research efforts into improving clinical care and
treatment for NAS infants. However, it is known, though less well-documented, that in utero
exposure to drugs, including opioids, can have significant effects on a child’s neurological
development long after the symptoms of NAS have dissipated (H. L. Johnson, Glassman, Fiks, &
Rosen, 1990; Nygaard, Moe, Slinning, & Walhovd, 2015; van Baar, Soepatmi, Gunning, &
Akkerhuis, 1994). Therefore, the purpose of this literature review is to summarize the findings of
both clinical and basic research studies that have examined the long-term effects of prenatal
opioid exposure (POE) within three primary categories: 1) Cellular and molecular development
within the central nervous system (CNS); 2) size, structure, connectivity and function of different
CNS regions and circuits; and 3) behavior and cognition. Combining current findings from bench
to bedside within these areas will ideally help identify gaps in our current knowledge and direct
future investigations into the longitudinal effects of opioids on neurological development.
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Part 1: Cellular and Molecular Development Within the CNS
Opioid receptors and their ligands
Our discussion of the long-term effects of in utero opioid exposure begins by examining
the effects opioids can have on critical cellular processes in the developing CNS. In mammals,
opioid drugs function primarily through opioid receptors, the three most prominent of which are
the µ, κ, and δ receptors. These G-protein coupled receptors are normally stimulated by
endogenous opioids such as endorphins, enkephalins, and dynorphins (Benarroch, 2012). The
endogenous opioid system is also differentially targeted by many prescription and illegal drugs.
Morphine and its derivatives (e.g. heroin, methadone, oxycodone, etc.) are primarily active at µ
receptors but are also κ and δ receptor agonists. In contrast, buprenorphine, a derivative of the
opiate alkaloid thebaine, has been shown to be a partial agonist at µ receptors but an antagonist
at κ and δ receptors (Welsh & Valadez-Meltzer, 2005). Furthermore, the major active metabolite
of buprenorphine, norbuprenorphine, is an agonist of δ receptors while a partial agonist of µ and
κ receptors (Huang, Kehner, Cowan, & Liu-Chen, 2001). A growing body of evidence indicates
that endogenous opioids and their receptors are vital to healthy nervous system development and
function, including analgesia, respiratory/cardiac function, intestinal transit, mood, hormone
secretion (Barnes, Jen, & Dunbar, 2004; Bottcher, Seeber, Leyendecker, & Wildt, 2017; Bueno
& Fioramonti, 1988; Callaghan, Rouine, & O'Mara, 2018; Dhawan et al., 1996; Irnaten et al.,
2003; Kwok, Devonshire, Bennett, & Hathway, 2014; Lalley, 2008), and neuronal
differentiation.
Neurons and neuronal progenitors
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µ- and κ-opioid receptors have been detected on the surfaces of both rodent and humanderived embryonic stem cells and neural progenitor cells, while binding of endogenous opioids
can induce embryonic stem cells to differentiate via the extracellular signal-regulated kinase
(ERK)/mitogen-activated protein (MAP) kinase signaling pathway (E. Kim et al., 2006; Sheng et
al., 2007; Tan, Cunningham, Joshi, Oei, & Ward, 2018). Preclinical studies suggest that the
localization of opioid receptors to different regions of the brain may have a significant impact on
development. Immature mice have been shown to have a higher percentage of µ-opioid receptor
expression within the subventricular zone (SVZ), a known site of neurogenesis, compared to
adult mice (Stiene-Martin et al., 2001). κ-opioid receptors similarly appear to be
developmentally downregulated in rats within sites of cellular proliferation and neurogenesis
(including the ventricular zone/SVZ and the dentate gyrus of the hippocampus) (Tan et al.,
2018). Given the importance of endogenous opioids and their receptors in the developing CNS,
an introduction of exogenous opioids, particularly in excess, could have a lasting, dramatic
impact on brain maturation.
In the clinic, pregnant mothers who are addicted to opioids commonly undergo
medication-assisted treatment (MAT) which combines less addictive prescription opioid drugs—
namely methadone or buprenorphine—with behavioral counseling in order to treat addiction and
achieve better health outcomes for the mother and child. However, emerging evidence asserts
that any opioid use during pregnancy, even when part of a medical treatment plan, can have
deleterious effects on the developing fetus that may vary depending on the opioid used (i.e.
morphine compared to methadone) (Burke & Beckwith, 2017; Kayemba-Kay’s & Laclyde,
2003). Preclinical investigations have shown opioids to stunt the proliferation and development
of neurons within the CNS, with prenatal exposure to buprenorphine in rats leading to reduced
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levels of neuronal specific protein markers (Neu-N and MAP-2) as well as stem/progenitor
biochemical markers of the neural lineage (e.g. nestin, Sox2, KLF4, and doublecortin) at
postnatal day 21 (Wu et al., 2014). These same rats showed decreased brain-derived neurotrophic
factor (BDNF) expression and signaling, with greater than 30% decreased mRNA expression in
both males and females as well as a nearly 20% reduction in phosphorylation of its high affinity
receptor TrkB. Since BDNF signaling via TrkB is vital for neurogenesis, axon growth, and
synaptic plasticity (Cohen-Cory, Kidane, Shirkey, & Marshak, 2010; Kramár et al., 2012), the
relationship between BDNF and exogenous opioids is likely clinically significant given that
plasma levels of BDNF were found to be increased in 2-day-old human infants diagnosed with
NAS compared to healthy infants (Subedi et al., 2017).
Altered expression of growth factors and signaling molecules do not appear to be the only
mechanism through which opioids affect neuronal development. In free-floating cultured rat
cortical neurospheres, buprenorphine was shown to reduce proliferation of neural
stem/progenitor cells in a dose-dependent manner (Wu et al., 2014). It has also been shown that
opioids alter neuronal expression of apoptotic proteins (namely caspase-3, Bcl-2, and Bax)
within rats, particularly within the hippocampus (Wang & Han, 2009). Dysregulation of
apoptosis could lead to inappropriate cell death, offering another potential pathway through
which these drugs may interfere with normal neuronal development. Not only is the number of
neurons in the developing CNS affected by the presence of opioids, but the growth and
maturation of those neurons also appears to be influenced. Excitatory pyramidal neurons isolated
from the somatosensory cortices of heroin-exposed mouse pups at postnatal day 3 showed fewer
and shorter dendrites compared to neurons from control pups (Lu, Liu, Long, & Ma, 2012),
indicative of impaired synaptic connectivity and interneuronal communication. These findings
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corresponded with a behavioral phenotype that showed reduced tendency to explore a familiar
object moved to a novel location in heroin-exposed mice at postnatal day 120, suggesting
impaired short-term spatial working memory (Lu et al., 2012); these and other behavioral
findings will be discussed in greater detail in Part 3 of this review.

Glial cells: Astrocytes
While a great deal of attention has been given to the development of neurons and their
precursors, glial cell development under the influence of opioids has been considerably less
studied (Figure 1). Astrocytes are the most numerous glial cell type in the CNS and serve many
vital functions, including the ability to regulate the development of synapses within the CNS
(Chung, Allen, & Eroglu, 2015). In mice, µ-opioid receptors have been confirmed on the surface
of astrocytes within the hippocampus, nucleus accumbens (NAc), and ventral tegmental area
(VTA), three brain regions associated with reward and addiction (Nam et al., 2018). The
presence of these receptors makes astrocytes susceptible to receptor-ligand interactions with both
endogenous and exogenous opioids. Morphine and other µ-opioid receptor agonists have been
shown to inhibit murine astrocyte growth and development by suppressing DNA synthesis, as
demonstrated by decreased bromodeoxyuridine (BrdU) incorporation (Hauser et al., 1996).
Evidence for the importance of astrocytes in the development of opioid addiction was provided
with mice that showed enhanced morphine conditioned place preference (CPP) after
administration of astrocyte-conditioned medium (ACM) into either NAc or cingulate cortex; the
ACM-injected mice actively chose to spend more time in a chamber paired with morphine
injections compared to either morphine alone or a chamber paired with saline injections (Narita
et al., 2006). This experiment was performed in adult mice, so future investigations will be
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necessary to determine whether prenatal opioid exposure would result in the same elicitation of
enhanced CPP that was observed.
Opioids have the potential to significantly impact astrocyte-neuronal interactions at
critical stages of early development, since cultured immortalized rat astrocytes subjected to
prolonged treatment with µ-opioid receptor agonists, including morphine, showed decreased
production of the glycoproteins thrombospondin-1 and -2 (TSP1 and 2) (Phamduong et al.,
2014). In the past two decades, preclinical investigations have revealed that astrocytes secrete
TSPs to initiate a signaling pathway that promotes synaptogenesis in developing neurons
(Christopherson et al., 2005; Eroglu et al., 2009) in a process critical to the formation of
intracortical connectivity and maturation of dendritic spines in the rodent brain (Risher et al.,
2018). Neurite outgrowth and excitatory synaptic density were both inhibited by chronic
morphine in rat astrocyte/neuron co-cultures (Ikeda et al., 2010), while the same study showed
decreased astrocyte expression of TSP1 in rat pups with repeated morphine injections. These
basic research findings take on heightened significance with the knowledge that astrocytes
represent a particularly highly specialized cell type in humans compared to lower animals,
including increased cortical TSP expression (Caceres, Suwyn, Maddox, Thomas, & Preuss,
2007; Oberheim, Wang, Goldman, & Nedergaard, 2006). Taken together, these results indicate
that the effect of opioids on the modulation of astrocyte signaling, particularly astrocytemediated synaptogenesis, may underlie many of the developmental aberrations associated with
POE in both animal models and humans.
Glial cells: Oligodendrocytes
Oligodendrocytes, another type of glial cell vital to the development and normal
functioning of the CNS, are primarily known for their role in forming myelin sheaths to facilitate
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saltatory conduction along the length of axons. Preclinical studies have shown that, as with other
cells within the CNS, oligodendrocytes express opioid receptors and can synthesize endogenous
opioids (Eschenroeder, Vestal-Laborde, Sanchez, Robinson, & Sato-Bigbee, 2012). Treatment of
pregnant rats with opioids has been shown to increase the expression of myelin-associated
proteins (Sanchez, Bigbee, Fobbs, Robinson, & Sato-Bigbee, 2008) and can lead to accelerated
oligodendrocyte maturation and myelination within the corpus callosum of the exposed pups
(Vestal-Laborde, Eschenroeder, Bigbee, Robinson, & Sato-Bigbee, 2014). In terms of clinical
relevance, given that accelerated myelination in humans has been associated with epileptic
seizures (Goldsberry, Mitra, MacDonald, & Patay, 2011) among other disorders, the interaction
of opioids and these myelinating glial cells during prenatal development certainly warrants
further investigation.
Glial cells: Microglia
Another glial cell type that expresses µ, κ, and δ opioid receptors are microglia (Chao et
al., 1996; Maduna et al., 2018; Shrivastava et al., 2017), the primary innate immune cell of the
CNS. Though not originally generated in the brain (they are derived from bone marrow prior to
migrating into the CNS), microglia play critical roles in numerous brain processes including
synaptic refinement and response to pathogens and injury (Schafer, Lehrman, & Stevens, 2013).
Basic research investigations have also implicated microglia in the formation of behaviors
associated with addiction. Schwarz and Bilbo (2013) demonstrated increased levels of the
immune receptor TLR4 on microglia in the NAc, which correlated with robust reinstatement of
morphine CPP in adulthood in rats that were exposed to morphine as adolescents. Interestingly,
similar effects were not observed in rats whose first exposure to morphine occurred during
adulthood, underscoring the importance of the timing of drug exposure in synaptic circuits that
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are still maturing. Compared to other cell types, relatively little is known about how microglia
respond to opioids during fetal development, but one recent study in rats exposed to prenatal
methadone demonstrated altered cortical microglial morphology at postnatal day 10 in
conjunction with upregulated inflammatory markers TLR4 and MyD88 (Jantzie et al., 2019).
The condensed cellular structure and decreased branching observed were consistent with the
“activated” microglial phenotype associated with neuroinflammation and disease (Bilbo &
Stevens, 2017). Whether these microglial changes persist into later ages, what role these cells
play in possible cognitive dysfunction after POE, and the impact of opioids on human microglia
remain crucial open questions.
Opioid receptor expression and activity
The expression and binding properties of opioid receptors, whether located on neurons or
glial cells, can be influenced by the presence of exogenous opioids. In a recent study, newborn
rat pups prenatally exposed to oxycodone showed decreased midbrain expression of the µ-opioid
receptor 1 (OPRM1) gene (Vassoler, Oranges, Toorie, & Byrnes, 2018), though this result was
seen only in females and not males. Additionally, µ-opioid receptor binding potential to an
enkephalin analog was shown to be significantly lower in the brains of one-day-old rat pups
whose mothers had received daily injections of 0.3 or 0.6 mg/kg buprenorphine during
pregnancy (Belcheva et al., 1998). The production and release of endogenous ligands that bind to
these receptors can similarly be affected by POE, as demonstrated by the finding that levels of
met-enkephalin were shown to be significantly lower in the striata of rats prenatally exposed to
morphine (Tempel, Yang, & Basheer, 1995). These results indicate a general trend wherein
hijacking of the endogenous opioid system by exogenous opioid exposure during early
development elicits a downregulation of endogenous opioid signaling. Importantly, however,
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since each of these studies was performed on 0- to 1-day-old pups, follow-up studies in older
animals as well as in human tissue will be necessary to determine the persistence and clinical
implications of the findings.
Part 2: Size, Structure, Connectivity and Function of CNS Regions and Circuits
POE stunts rates of growth and development
Widespread changes in cellular function and morphology associated with in utero opioid
exposure are often accompanied by observable changes in the size, structure, and function of
entire brain regions and the pathways that connect them. For decades, researchers have observed
lower birth weights and smaller head circumferences in POE children (H. L. Johnson, Diano, &
Rosen, 1984; Ornoy, Segal, Bar-Hamburger, & Greenbaum, 2001; Wilson, McCreary, Kean, &
Baxter, 1979), a trend that holds in rats and mice as well (Ford & Rhines, 1979; Wu et al., 2014;
Zagon & McLaughlin, 1977). In general, low birth weight in humans (regardless of cause) has
been associated with higher rates of behavioral problems throughout childhood and early
adolescence, often resulting in poor scholastic performance (McCormick, Gortmaker, & Sobol,
1990; Taylor, Margevicius, Schluchter, Andreias, & Hack, 2015). Additionally, low birth weight
in infants with prenatal drug exposure is significantly correlated with higher rates of mortality in
the first two years of life (Ostrea, Ostrea, & Simpson, 1997), further compounding the issues
involved in caring for these children.
Other structural deficits associated with POE in humans are not outwardly apparent and
can only be observed through medical imaging (Table 1). As early as 18-22 weeks gestation,
ultrasound studies have found that fetuses whose mothers were undergoing methadone
maintenance therapy had significantly larger thalamic diameter-to-head circumference ratios
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compared to a control group (0.90 ± 0.1 versus 0.87 ± 0.1 mm; p = 0.01) (Schulson et al., 2014).
One ultrasound study observed abnormally small, slit-like ventricles in 13 out of 16 NASaffected 1-month-old infants compared to 0 out of 11 control infants (E Pasto et al., 1985).
Magnetic resonance imaging (MRI) studies, which have previously shown reduced white matter
and grey matter within the brains of habitual opioid-using adults (Upadhyay et al., 2010; Y.
Yuan et al., 2009), revealed certain regions in the brains of prenatal opioid-exposed children
(including the basal ganglia, thalamus, and cerebellar white matter) to be significantly smaller
compared to age-matched control children after adjusting for intracranial volume and
birthweight. This result was consistent in both infants (Q. Yuan et al., 2014) and children 10-14
years of age (Sirnes et al., 2017). More widespread deficits were observed in an MRI study
examining 17-22-year-olds whose mothers had abused multiple drugs, including heroin, during
pregnancy; these individuals had significantly smaller whole brain, cerebral cortex, cerebral
white matter, basal ganglia, pallidum, thalamus, and cerebellar white matter volumes compared
to controls (Nygaard et al., 2018). Taken together, these results show that the smaller brain
region sizes observed in POE infants are wide-ranging and can persist into adulthood.
Potential impact of POE on the mesolimbic dopamine pathway
In studies of opioid addiction and the CNS, much attention has been focused on brain
regions associated with the mesolimbic dopamine pathway. Also known as the dopamine reward
pathway, this pathway works to encode experiences as pleasurable and reinforce future behavior
to seek out those experiences again (Figure 2). This process begins in the VTA, where the cell
bodies of dopaminergic neurons extend axonal processes to other regions of the brain including
the NAc, hippocampus, and prefrontal cortex (PFC) (Adinoff, 2004; J. E. Lisman & Grace,
2005). Opioids affect the reward pathway by binding to opioid receptors on the surface of
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interneurons within the VTA, thus inhibiting release of the inhibitory neurotransmitter GABA
and subsequently disinhibiting the release of dopamine by nearby dopaminergic neurons (S. W.
Johnson & North, 1992). In the NAc, increased phasic release of dopamine in response to
external stimuli has been shown to reinforce pleasurable behaviors including eating food,
engaging in sexual activity, or taking drugs of abuse (Lingford-Hughes & Kalk, 2012). The PFC,
the brain region most associated with decision-making and impulse control, projects to the NAc
and modulates its activation (Pierce & Kumaresan, 2006). The hippocampus appears to form a
functional loop with the VTA to promote seeking out novel experiences and expecting reward
when engaging in behaviors that were pleasurable in the past (J. E. Lisman & Grace, 2005).
Currently, little is known about how POE affects the formation and strengthening of the
mesolimbic dopamine circuit, with the majority of the findings being speculative based on
changes in reward seeking or depressive-like behaviors. Since µ-opioid receptors in the VTA
have been shown to regulate dopaminergic and serotonergic outputs to PFC, NAc and other brain
regions (K. L. Smith et al., 2019), one can envision a scenario in which prenatal opioids would
hamper multiple neurotransmitter systems during periods for neurodevelopment. Therefore,
future studies examining changes in the size, structure, and function of these brain regions will
be important in understanding how reward processing and motivation might be altered in
affected children as they age.
Sex differences with POE
Sex hormones produced by either the ovaries or testes are vital to the normal fetal
development. Within the CNS, the presence of male or female specific hormones is necessary for
sex-specific differences in the size and structure of certain brain regions across species, including
humans (A A Ehrhardt & Meyer-Bahlburg, 1979; Xin, Zhang, Tang, & Yang, 2019). Sex
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hormones may also modify the effects of POE on neurological development and function. The
expression of opioid receptors within the brains of rats has been shown to be influenced by the
presence of estrogen and progesterone (Cruz et al., 2015), but the exact role of ovarian hormones
in the development of the endogenous opioid system remains unclear. Additional evidence for an
interaction between sex hormones and opioids during development can be observed in the
presentation of human infants with NAS. In one retrospective study, it was observed that male
infants were more likely than females to be diagnosed with NAS (1.18 odds ratio after adjusting
for maternal age, race, and education level) and were more likely to require pharmacologic
treatment after being diagnosed (1.24 adjusted odds ratio) (Charles et al., 2017). Sex differences
in head circumference (35.78 ± 0.27 cm in males compared to 33.40 ± 1.43 cm in females;
p=0.035) and types of symptoms (e.g. females showed greater instances of diarrhea, excessive
sucking, tremors, sleep disturbances, and crying; males were more likely to have hyperactive
Moro reflex and nasal stuffiness) have also been observed (Stevens et al., 2018). Further
investigation is required to identify the cellular and molecular mechanisms that underlie these
sex-biased observations.
Insight from functional studies
Electrophysiology is commonly used in preclinical studies to investigate synaptic
conduction within and between brain regions, providing insight into neuronal function and
network plasticity. One frequently studied plasticity phenomenon is long-term potentiation
(LTP), wherein a sustained increase in excitatory postsynaptic potential (EPSP) is observed after
repeated stimulation of a presynaptic neuron; this result is often interpreted as a strengthening of
synaptic transmission in that circuit (Bliss & Lomo, 1973). With regard to the hippocampus, LTP
is generally thought to represent the process whereby long-term, episodic memories are formed
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(J. Lisman, Cooper, Sehgal, & Silva, 2018). In adult rats prenatally exposed to morphine,
maintenance and longevity of LTP within their hippocampi were shown to be attenuated
compared to rats treated with saline (Villarreal, Derrick, & Vathy, 2008). This finding may offer
mechanistic insight into the observation that POE is associated with deficits in learning and
memory (Chen et al., 2015; Slamberova et al., 2001; Wang & Han, 2009). Intriguingly, rats
prenatally exposed to morphine showed significant improvements in LTP and the Morris water
maze (spatial learning task) with exercise and enriched environment housing (Ahmadalipour,
Ghodrati-Jaldbakhan, Samaei, & Rashidy-Pour, 2018), suggesting a possible therapeutic
intervention to alleviate some of the long-term cognitive deficits associated with early life drug
exposure.
Given the invasive nature of electrophysiological techniques, certain imaging modalities,
such as functional magnetic resonance imaging (fMRI), are currently the predominant
methodology for clinical investigations into neuronal activity. Specifically, fMRI uses changes in
blood flow to approximate the level of activity within specific brain regions while a patient
performs certain tasks. An fMRI study of POE children between the ages of 9 and 12 years
showed significantly greater activity within their prefrontal cortices (involved in inhibitory
control and executive function) during working memory-selective attention tasks compared to
unexposed children (Sirnes et al., 2018). Another fMRI study investigated adolescents (12-15
years of age) prenatally exposed to heroin and other drugs while performing a visuospatial
working memory task when compared to a control group (Schweitzer et al., 2015). Though
overall performance on the task was similar between groups, the drug-exposed children showed
aberrant circuit activation that resulted in less efficient signaling; the authors indicated that this
type of function was reminiscent of developmentally immature brains. Taken together, these
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findings suggest that the brains of POE children have impaired interneuronal connectivity and
therefore must compensate through other suboptimal mechanisms.
Part 3: Behavior and Cognition
Findings from rodent behavioral studies
A variety of behavioral and cognitive deficits have been documented in POE animal
models (Table 2) and humans, which may represent consequences of the anatomical and
physiological changes discussed thus far. Tests of anxiety-type behaviors in animal models have
shown significant differences between drug-exposed and control subjects. Adult rats whose
mothers were injected with morphine during pregnancy were shown to spend less time both in
the light compartment of a light/dark box and while exploring the open arms of an elevated plus
maze compared to rats whose mothers received saline (Ahmadalipour et al., 2015; Klausz et al.,
2011). These test results are suggestive of more pronounced anxious phenotypes among prenatal
morphine-exposed rats; similar behaviors were observed in rats prenatally exposed to
buprenorphine and methadone as well (Chen et al., 2015). Whether this anxious behavioral
profile reflects changes within the mesolimbic dopamine pathway and altered sensitivity to
dopamine has yet to be determined.
Given the importance of opioids in reward processing, it is not surprising that rewardseeking and depressive behaviors are affected in POE animals. Adult rats exposed to morphine in
utero showed a greater preference for a saccharin/water solution over pure water compared to
control rats (with females showing an increased hedonic effect compared to males), indicating a
generally elevated response to pleasurable stimuli (Gagin, Cohen, & Shavit, 1996). Differences
are also seen in exposed animals when faced with unpleasant stimuli, as when rats prenatally
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exposed to buprenorphine showed reduced escape-oriented behaviors in the forced swimming
and tail suspension tests; this result was interpreted as POE rats exhibiting greater depressive
behavior than control rats (Hung et al., 2013; Klausz et al., 2011; Wu et al., 2014). Though
merely speculative at this point, POE-induced changes in connectivity or strength of the
mesolimbic dopamine reward pathway could certainly contribute to these trends of elevated
response to rewarding stimuli and greater depressive behavior in response to unpleasant stimuli.
Studies utilizing memory tests have consistently shown worse performance by POE mice
and rats compared to control rodents. Rats prenatally exposed to morphine, methadone, or
buprenorphine subjected to tests of novel object recognition on postnatal day 44 were shown to
have impaired recognition memory compared to control rats (Chen et al., 2015). When tested
with the Morris water maze on postnatal day 30, rats who underwent prenatal heroin exposure
took significantly longer than unexposed rats to follow visual cues and swim to a platform they
had previously located, indicating deficits in learning and memory (Wang & Han, 2009).
Another investigation into learning and memory deficits used a symmetrical maze and a radial
arm maze (RAM) to show significant sex-related differences in the ability of prenatal morphineexposed rats to solve the mazes (Slamberova et al., 2001). Male rats required less time to
complete the symmetrical maze, while both sexes showed deficits in completing the RAM in a
similar amount of time to sex-matched controls. The presence or absence of ovarian hormones
was implicated as the reason for these sex-related differences, since ovariectomized POE females
had poor performance on RAM delay trials (measuring working spatial memory) that could be
rescued by hormone replacement injections.
Effects of POE on human cognition
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Studies of behavior and cognitive ability in animals can yield valuable insight into
possible mechanisms of opioids affecting normal CNS development, but ultimately these
evaluations must performed on humans. Studies use a variety of scales and tests to evaluate
human cognitive function at different developmental stages. A recent meta-analysis by Yeoh et
al. (2019) of 26 human POE studies provides an excellent overview of the current knowledge, so
we will only highlight a select few in the current discussion. Male infants with a history of
prenatal opioid exposure have been shown to score higher than females on tests of habituation,
which measure the ability of the infant to ignore extraneous environmental stimuli (Jones,
O'Grady, Johnson, Velez, & Jansson, 2010). One of the earliest published human POE studies
showed that children aged 3 to 6 years old who were prenatally exposed to heroin performed
worse on the General Cognitive Index and on the perceptual performance, quantitative, and
memory subtests of the McCarthy Scales of Children’s Abilities (Wilson et al., 1979). Several
years later, a study compared a group of 12-month-old children that had been prenatally exposed
to methadone to an unexposed, age-matched control group by utilizing the Bayley Scales of
Infant Development. It was found that 20% of the methadone exposed group had Mental
Development Index scores indicative of developmental delay, while only 4% of the unexposed
children had such low scores (H. L. Johnson et al., 1984). A more recent study used the second
edition of the Bayley Scales of Infant Development (Bayley-II) to evaluate a group of boys
whose mothers had abused multiple drugs, including heroin, during pregnancy. The average
scores for these children at years 1, 2, and 3 were, respectively, 9.7, 12.9, and 10.3 points lower
than the average scores for an unexposed control group (Nygaard et al., 2015). The same cohort
scored 15.4 points lower on the McCarthy Scales of Children's Abilities at age 4.5 and 14.8
points lower on the Wechsler Intelligence Scale for Children at age 8.5, suggesting that
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diminished cognitive ability among prenatally exposed children does not improve over time. An
analysis of standardized test scores in New South Wales, Australia also provides evidence that
prenatally exposed children do not catch up with non-exposed peers in terms of cognitive ability.
A cohort of children who had been diagnosed with NAS as infants scored lower on the National
Assessment Program: Literacy and Numeracy (NAPLAN) than the statewide average and were
more likely to not meet a minimum standard score in grades 3, 5, and 7 (ages 8–9, 10–11, and
12–13 years respectively) (Oei et al., 2017). These persistent trends imply that opioid exposure
in early stages of development lead to lasting, detrimental cognitive changes.
While standardized tests can be used to reveal deficits in cognitive function associated
with POE, in some cases this exposure appears to negatively impact cognition to the point where
the affected child develops a diagnosable disability. A study in Tennessee found that a group of
school aged children (ages 3-8 years) with a history of NAS were more likely to have been
evaluated for, diagnosed with, or treated for an educational disability compared to an agematched control group of children (Fill et al., 2018). The authors of this study also noted that
children in the NAS group required specialized classroom therapies or services at the rate of
15.6% compared to 11.7% in the control group (p<0.0001). Another study used the Truven
Health Analytics’ Multi-State Medicaid Database to follow the psychiatric outcomes of over
1,000 children who had been diagnosed with NAS as infants. Within their first 5 years of life,
these children were more than twice as likely to have been diagnosed with either disturbance of
conduct, hyperkinetic syndrome of childhood, adjustment reaction disorder, or an intellectual
disability compared to children with no history of NAS (Laura J. Sherman, Mir M. Ali, Ryan
Mutter, & Justine Larson, 2019). Given the increasing rates of NAS nationwide, observations
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such as these highlight the importance of POE research to an educational system that will have to
accommodate the specific needs of the affected children.
Longitudinal studies: Tracking the effects of POE into adulthood
The vast majority of studies comparing cognitive function and mental health between
POE individuals to non-exposed controls are focused on children and adolescents. Given that the
rise in opioid addiction and overdose is a relatively recent phenomenon (Kolodny et al., 2015),
there are only limited longitudinal studies following subjects into adulthood. One study that
included adult subjects examined a group of individuals 17-21 years of age whose mothers had
abused heroin and other drugs during pregnancy. It was found that members of this drug-exposed
group had significantly higher rates of attention deficit disorder/attention hyperactivity disorder
(ADD)/ADHD) and substance abuse disorder compared to a non-exposed age-matched control
group (Nygaard, Slinning, Moe, & Walhovd, 2017). In addition, the exposed group performed
significantly poorer on the Wechsler Abbreviated Scale of Intelligence (WASI) test of general
mental abilities and on multiple tests of memory compared to the non-exposed control group
(Nygaard et al., 2017).
To date, few studies have investigated whether POE predisposes an individual towards
developing addiction later in life. Although it is well-accepted that many forms of addiction
carry some level of heritability (Ducci & Goldman, 2012), only a handful of published basic
research studies have attempted to isolate POE as the sole potential contributing factor to
increased risk of developing an opioid use disorder. One study showed that rats prenatally
exposed to morphine demonstrated increased morphine self-administration as adults compared to
non-exposed rats (Hovious & Peters, 1985). In another study, rats prenatally exposed to
morphine showed enhanced conditioned place preference when treated with morphine as adults
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(Gagin, Kook, Cohen, & Shavit, 1997). Given the involvement of opioids in the development of
the reward pathway, it is possible that prenatal opioids may predispose the brain towards
addiction to rewarding stimuli other than opioids. Rats prenatally exposed to morphine
demonstrated increased self-administration of both the opioid drug heroin and also cocaine, a
stimulant drug with an entirely different mechanism of action than opioids (Ramsey, Niesink, &
Van Ree, 1993). Considering the lack of longitudinal data on humans, the field would greatly
benefit from animal studies that subject prenatally-exposed pups to rigorous behavioral testing
specifically designed to measure their impulsivity and drug seeking behavior at various stages of
development and maturity. Such studies may better illuminate the role of POE in the
development of addictive behaviors later in life, thereby informing treatment and prevention
strategies for human children born with NAS.
Confounds to consider when interpreting the impact of POE on development
Potentially, there are many confounding variables to consider in studies of cognitive
development among children born to parents with substance abuse disorders. Socioeconomic
status is perhaps the most relevant of these confounds, as it is highly correlated with rates of
substance abuse, quality of perinatal care, and success in education (M. K. Kim et al., 2018;
LaGasse, Seifer, & Lester, 1999; M. E. Patrick, Wightman, Schoeni, & Schulenberg, 2012;
Thomson, 2018). It is understandably impossible to remove all variables except for opioid
exposure when conducting a study on human patients. Theoretically then, studies of children
born with NAS who went on to be raised by someone other than the birth mother may yield
valuable insight. However, even when they are adopted at an early age (e.g. younger than 1 year)
and raised in a nurturing environment, children born to heroin-addicted mothers have been
shown to have a higher rate of inattention and behavioral problems from school-age to late
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adolescence than matched non-drug-exposed controls (Nygaard et al., 2017; Ornoy, 2003).
Further compounding the issue of NAS heterogeneity is the use of other drugs in conjunction
with opioids during pregnancy. Polysubstance use is a growing concern in the field of opioid
abuse and is positively correlated with the diagnosis of NAS (Roth, Loudin, Andrews, Evans, &
Davies, 2020). One drug in particular, the anticonvulsant gabapentin, has been increasingly coabused along with opioids (R. V. Smith, Havens, & Walsh, 2016), resulting in Schedule V
controlled substance classification in several states (including several located in the Appalachian
region of the Eastern United States). Though gabapentin was initially believed to have no
potential for abuse or addiction (Vickers Smith et al., 2018), mounting evidence suggests that
this is not the case. One survey of opioid use disorder patients found that about 1 in 4 also used
gabapentin for nonmedical reasons (Bastiaens, Galus, & Mazur, 2016). Some patients self-report
that the co-abuse serves to potentiate the experienced opioid high (Baird, Fox, & Colvin, 2014).
While this may be due to the activity of gabapentin at the α2δ-1 subunit of the L-type voltageregulated calcium channels to inhibit neurotransmitter release and/or reduce neuronal
hyperexcitability (Patel & Dickenson, 2016), this explanation requires further investigation and
is subject to debate. Regardless, behaviors not commonly observed in NAS, such as tongue
thrusting, back arching, and eye wandering, have been observed in children born to mothers who
co-abused both opioids and gabapentin (Loudin et al., 2017). These infants also required
gabapentin weaning in addition to being treated for opioids, resulting in significantly increased
hospital lengths-of-stay. Drugs taken in addition to opioids may lead to either diminished,
enhanced, or significantly altered changes in developmental outcomes in prenatally exposed
children, making it difficult to parse out the exact role or mechanism of opioids in these changes.
In the case of gabapentin, prenatal exposure to this drug alone would likely impact the formation
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of neuronal networks in the developing fetus by inhibiting the synaptogenic TSP pathway
(discussed in Part 1) via their shared receptor, α2δ-1 (Walker, Risher, & Risher, 2020); the
combination of prenatal opioids and gabapentin would therefore represent a critical threat to
long-term brain connectivity and function.
Conclusion
In summary, this review has summarized what is known and what important questions
still remain about the effects of opioids on the developing and maturing nervous system. In our
attempt to maximize the breadth of the review, we have collated findings from both preclinical
and human studies. However, when considering the animal models of POE, a critical caveat
should be kept in mind: despite the widespread use of rodents as in vitro and in vivo models for
human development and the key insights gained from these models, the timeline for rodent
neurodevelopment does not correlate directly with that of humans. A newborn mouse, for
example, is approximately neurodevelopmentally equivalent to a human fetus in the late second
trimester (Ross, Graham, Money, & Stanwood, 2015). The significant differences between
rodent and human fetal development warrant the need for noninvasive, ethical methods of
studying human tissues at early developmental stages. Tissue from post-mortem humans has
been effectively and reproducibly used to study the expression of opioid-receptor-encoding
mRNA molecules, demonstrating their presence in the brain, spinal cord, and peripheral organs
such as the intestines (Peng, Sarkar, & Chang, 2012). In addition, recent advances in threedimensional in vitro culture techniques have led to brain organoids derived from induced human
pluripotent stem cells that have been used to study changes in human protein expression and cell
maturation. This model system is non-invasive and allows for the study of functional, living,
human tissue (Di Lullo & Kriegstein, 2017), making it a potentially invaluable tool in the study
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of the effects of opioid exposure on the developing human brain. These recent models could lead
to a more translational understanding of the natural processes disrupted by exogenous opioids
and elucidate the role of glial cells in these processes. Going forward, it would be constructive to
pursue the opportunities that are now available to explore the effects of opioid exposure on
human CNS development at the cellular and molecular level. In addition, further studies into
how interactions between neurons and glial cells are affected by prenatal drugs and what role
these interactions play in the pathology of NAS could provide key insights into potential future
treatments and neurodevelopment as a generalized process. Finally, while many studies have
investigated the effects of opioids in isolation on neurodevelopment, substance users rarely abuse
only one drug. The interactions of multiple drugs may have unique effects on the development of
exposed children that deserve additional investigation.
One of the primary goals of studying the effects of POE on human neurodevelopment is
to raise awareness in the parents of the affected children as well as the clinicians and other
caregivers responsible for the medical, psychiatric and psychological care of those children.
Improved understanding of the effects of POE on behavioral and cognitive development,
particularly during school age and adolescence, may inform parents and educators looking to
meet the unique developmental and educational needs of impacted children. Behavioral studies
targeting POE as an adverse early life event could explore whether or not the changes in
development caused by this exposure predispose a child to develop addiction later in life. In
regions of the United States that are struggling in terms of education and economic development,
such as Central Appalachia where the rates of NAS can exceed 10% of all live births (Umer et
al., 2019), the information gained from such behavioral studies could be vital to improving
quality of life for those affected by opioid abuse. Therefore, further studies examining NAS, the
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underlying molecular and cellular mechanisms involved, and its short and long-term effects on
neurological development are critical to successfully combat the ongoing societal effects of
opioid addiction.
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Table 1: Summary of the effects of prenatal opioids observed in different brain regions in either
humans or rodents

Effects of Prenatal Opioids on Regions of the Brain
Brain Region

Functions

POE Effect

Basal Ganglia

Motor control, motor learning,
executive function, emotions

Thalamus

Integrate and relay sensory
information, sleep and
wakefulness

Humans: Decreased size in infants, 1014-year-olds, and 17-22-year-olds (Yuan
et al., 2014; Sirnes et al., 2017; Nygaard
et al., 2018)
Humans: Decreased size in 10-14-yearolds and 17-22-year-olds (Sirnes et al.,
2017; Nygaard et al., 2018)

Cerebellum

Coordination of voluntary
motor function, balance,
posture

Humans: Reduced white matter volume
in 10-14-year-olds and 17-22-year-olds
(Sirnes et al., 2017; Nygaard et al., 2018)

Prefrontal
cortex

Inhibitory control, executive
function, logical reasoning,
planning, working memory

Hippocampus

Long-term memory

Humans: Greater activity during working
memory-selective attention tasks in 912-year-olds (Sirnes et al., 2018)
Rats: Altered expression of apoptotic
proteins (Wang et al., 2009); Attenuated
maintenance and longevity of LTP
(Villarreal et al., 2008)

Cerebral Cortex

Speech, language, decision
making, learning, memory,
vision, motor control,
somatosensory processing, etc.

Humans: Decreased size in 17-22-yearolds (Nygaard et al., 2018)

Corpus
Callosum

Connection and
communication between
hemispheres

Rats: Accelerated oligodendrocyte
maturation and myelination (VestalLaborde et al., 2014)

Striatum

Goal oriented voluntary
movement, reward and
reinforcement

Rats: Decreased levels of met-enkephalin
(Tempel et al., 1995)

Ventricles

Production and circulation of
cerebrospinal fluid

Humans: Decreased size and slit-like
shape in infants (Pasto et al., 1985)
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Table 2: Observed effects of prenatal opioid exposure on rodent behavior

Behavioral Effects of Prenatal Opioids
Aspect of
Behavior
Anxiety

Depression

Reward Seeking

Memory

POE Effect
Decreased time in open arms of Elevated
Plus Maze; Decreased time in light
compartment of Light/Dark Box (Chen et al.,
2015; Ahmadalipour et al., 2015; Klausz et
al., 2011)
Longer immobility time in tail suspension
and forced swim test (Wu et al., 2014; Klausz
et al., 2011; Hung et al., 2013)
Greater preference for saccharin water
(Gagin et al., 1996); Increased morphine selfadministration (Hovious and Peters, 1985);
Enhanced conditioned place preference
(Gagin et al., 1997)
Longer escape latency in Morris Water Maze
(Wang and Han, 2009); Reduced retention in
novel object recognition test (Chen et al.,
2015); Longer completion time in radial arm
maze (Slamberova et al., 2001)
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Figure 1: Glial cell function in development. A) Confocal reconstruction of green fluorescent
protein (GFP)-tagged astrocyte (green) co-labeled with glial acidic fibrillary protein (GFAP;
magenta; scale bar, 10 µm). Red punctate staining indicates locations of excitatory synapses,
which are ensheathed by astrocytic processes (figure courtesy of Dr. Louise Risher, Marshall
University). Astrocytic support of synapses is proposed to be disrupted by chronic opioid
exposure. B) Electron micrograph showing cortical axons (arrows) previously myelinated by
oligodendrocytes (scale bar, 0.5 µm). Accelerated myelination has previously been reported with
POE. C) Confocal image of microglial cell body and processes labeled with Iba1 (scale bar, 5
µm). Microglial activation may represent a primary pathogenic mechanism following fetal
exposure to opioids (Figures in B and C courtesy of Dr. W. Christopher Risher).

Figure 2: The mesolimbic dopamine pathway. Map of A) human and B) rodent brain
highlighting areas associated with addiction/reward/withdrawal and the connections between
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them: ventral tegmental area (VTA), hippocampus (Hippo.), amygdala (Amyg.), anterior
cingulate cortex (ACC), nucleus accumbens (NAc), and prefrontal cortex (PFC).

